RxDoctor Payments Data

Laura Fick, APRN

Adult Health · Lincoln, NENPI 1366750283

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Abbott at 27.8% of the total. That places this record below the midpoint for adult health clinicians in NE, where the typical reported total is $315.

$191in general payments, 2019–2025

Across 10 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$53
  • Novo Nordisk$37
  • Nalu Medical, Inc.$32
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$24
  • Sanofi Pasteur Inc.$17
  • AbbVie$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$191 in reported general payments places this provider in the 40th percentile of 58 adult health providers in Nebraska.

See all adult health providers in Nebraska

Medicare billing

Part B allowed, 2024
$84,137
Medicare patients
396
Services billed
3,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide178$214,867
XareltoRivaroxaban64$76,905
FarxigaDapagliflozin Propanediol64$45,647
JardianceEmpagliflozin41$41,163
EliquisApixaban59$40,868
Tresiba Flextouch U-200Insulin Degludec16$18,812
TrulicityDulaglutide19$16,836
Oxycodone Hcl35$14,327
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$13,247
QuliptaAtogepant12$13,186
JanuviaSitagliptin Phosphate15$11,672
RestasisCyclosporine15$8,586
Combivent RespimatIpratropium/Albuterol Sulfate14$6,794
TradjentaLinagliptin12$5,900
Tresiba Flextouch U-100Insulin Degludec12$5,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$214,867178 claims
AbbVieQulipta, Restasis, Synthroid$14$26,45170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 58 adult health providers in Nebraska.

Other adult health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →